At a glance
- Originator Nonindustrial source; Xenova Group
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Aug 2002 Discontinued - Preclinical for Cancer in England (unspecified route)
- 19 Jul 1999 New profile
- 19 Jul 1999 Preclinical development for Cancer in England (Unknown route)